Title |
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib
|
---|---|
Published in |
Investigational New Drugs, June 2010
|
DOI | 10.1007/s10637-010-9458-7 |
Pubmed ID | |
Authors |
Romain Coriat, Stanislas Ropert, Olivier Mir, Bertrand Billemont, Stanislas Chaussade, Pierre-Philippe Massault, Benoit Blanchet, Olivier Vignaux, François Goldwasser |
Abstract |
Recently, pneumatosis intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on pneumatosis intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to pneumatosis intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that pneumatosis intestinalis is a probable class-effect of anti-VEGF agents. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
New Zealand | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 25 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 4 | 16% |
Researcher | 3 | 12% |
Librarian | 1 | 4% |
Student > Bachelor | 1 | 4% |
Other | 1 | 4% |
Other | 2 | 8% |
Unknown | 13 | 52% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 32% |
Agricultural and Biological Sciences | 2 | 8% |
Economics, Econometrics and Finance | 1 | 4% |
Social Sciences | 1 | 4% |
Sports and Recreations | 1 | 4% |
Other | 0 | 0% |
Unknown | 12 | 48% |